{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:43:08Z","timestamp":1785552188440,"version":"3.56.0"},"reference-count":43,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Brepocitinib is a TYK2\/JAK1 inhibitor in development for the treatment of several immunologic diseases. The efficacy and safety of oral brepocitinib were assessed in participants with moderately\u2010to\u2010severely active psoriatic arthritis (PsA) for up to 52\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this placebo\u2010controlled, dose\u2010ranging, phase IIb study, participants were randomized to receive 10 mg, 30 mg, or 60 mg of brepocitinib once daily or placebo, advancing to 30 mg or 60 mg of brepocitinib once daily at week 16. The primary endpoint was the response rate according to the American College of Rheumatology criteria for 20% improvement (ACR20) in disease activity at week 16. Secondary endpoints included response rates according to the ACR50\/ACR70 response criteria, 75% and 90% improvement in the Psoriasis Area and Severity Index (PASI75\/PASI90) score, and minimal disease activity (MDA) at weeks 16 and 52. Adverse events were monitored throughout the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 218 participants were randomized and treated. At week 16, the brepocitinib 30 mg and 60 mg once daily groups had significantly greater ACR20 response rates (66.7% [<jats:italic>P<\/jats:italic> =\u20090.0197] and 74.6% [<jats:italic>P<\/jats:italic> =\u20090.0006], respectively), versus the placebo group (43.3%), and significantly higher ACR50\/ACR70, PASI75\/PASI90, and MDA response rates. Response rates were maintained or improved through week 52. Adverse events were mostly mild\/moderate; serious adverse events (15) in 12 participants (5.5%) included infections in 6 participants (2.8%) in the brepocitinib 30 mg and 60 mg once daily groups. No major adverse cardiovascular events or deaths occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment with brepocitinib at dosages of 30 mg and 60 mg once daily was superior to placebo at reducing signs and symptoms of PsA. Brepocitinib was generally well tolerated throughout the 52\u2010week study, with a safety profile consistent with those found in other brepocitinib clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.42519","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T03:01:13Z","timestamp":1684292473000},"page":"1370-1380","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Efficacy and Safety of the <scp>TYK2<\/scp>\/<scp>JAK1<\/scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb<\/scp> Randomized Controlled Trial"],"prefix":"10.1002","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"first","affiliation":[{"name":"Swedish Medical Center\/Providence St. Joseph Health and University of Washington  Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9105","authenticated-orcid":false,"given":"Philip","family":"Helliwell","sequence":"additional","affiliation":[{"name":"University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Silwinska\u2010Stanczyk","sequence":"additional","affiliation":[{"name":"REUMATIKA\u2013Centrum Reumatologii NZOZ  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Miakisz","sequence":"additional","affiliation":[{"name":"Twoja Przychodnia Centrum Medyczne Nowa S\u00f3l  Nowa S\u00f3l Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ostor","sequence":"additional","affiliation":[{"name":"Monash University, Cabrini Hospital, and Emeritus Research  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiankun","family":"Sun","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Sikirica","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Winnette","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolun","family":"Qiu","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Feng","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean S.","family":"Beebe","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Martin","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez383"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00209-4"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00305-z"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2495"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2019.09.005"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00917"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.03.962"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"S030","DOI":"10.1093\/ecco-jcc\/jjab075.032","article-title":"OP33 Oral ritlecitinib and brepocitinib in patients with moderate to severe active ulcerative colitis: data from the VIBRATO umbrella study","author":"Sandborn W","year":"2021","journal-title":"J Crohns Colitis"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_7_24_1","first-page":"80","article-title":"The GO\u2010DACT protocol: a multicentre, randomized, double\u2010blind, parallel\u2010group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy","volume":"43","author":"Vieira\u2010Sousa E","year":"2018","journal-title":"Acta Reumatol Port"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23568"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_7_29_1","volume-title":"SF\u201036 health survey: manual and interpretation guide","author":"Ware JE","year":"1993"},{"key":"e_1_2_7_30_1","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella D","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25282-2"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03522.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.05.012"},{"issue":"2","key":"e_1_2_7_35_1","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea JJ","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202859"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1046"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00010-2"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S219586"},{"key":"e_1_2_7_40_1","unstructured":"PfizerInc.Highlights of prescribing information\u2013Xeljanz\/Xeljanz XR.2021. URL:http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959."},{"key":"e_1_2_7_41_1","unstructured":"AbbVie Biotechnology Ltd.Highlights of prescribing information\u2013upadacitinib.2022. URL:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211675s004lbl.pdf."},{"key":"e_1_2_7_42_1","unstructured":"LillyUSA LLC.Highlights of prescribing information\u2013Olumiant (baricitinib).2021. URL:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207924s004lbl.pdf."},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab774"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:23:17Z","timestamp":1759933397000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/art.42519"],"URL":"https:\/\/doi.org\/10.1002\/art.42519","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"2022-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}